HSPBP1

Summary

HSPBP1 (HSPA (Hsp70) binding protein 1, HGNC:24989) is a protein-coding gene on chromosome 19q13.42, encoding Hsp70-binding protein 1 (Q9NZL4). Inhibits HSPA1A chaperone activity by changing the conformation of the ATP-binding domain of HSPA1A and interfering with ATP binding.

Enables molecular sequestering activity and ubiquitin protein ligase binding activity. Involved in positive regulation of proteasomal ubiquitin-dependent protein catabolic process and positive regulation of protein ubiquitination. Is active in extracellular space.

Source: NCBI Gene 23640 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 78 total — 2 pathogenic
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_012267

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24989
Approved symbol	HSPBP1
Name	HSPA (Hsp70) binding protein 1
Location	19q13.42
Locus type	gene with protein product
Status	Approved
Aliases	FES1
Ensembl gene	ENSG00000133265
Ensembl biotype	protein_coding
OMIM	612939
Entrez	23640

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 24 protein_coding

ENST00000255631, ENST00000433386, ENST00000585698, ENST00000585927, ENST00000587551, ENST00000587922, ENST00000587959, ENST00000588971, ENST00000593263, ENST00000874509, ENST00000874510, ENST00000874511, ENST00000874512, ENST00000874513, ENST00000874514, ENST00000874515, ENST00000874516, ENST00000933732, ENST00000933733, ENST00000933734, ENST00000933735, ENST00000933736, ENST00000957929, ENST00000957930

RefSeq mRNA: 3 — MANE Select: NM_012267 NM_001130106, NM_001297600, NM_012267

CCDS: CCDS33111

Canonical transcript exons

ENST00000433386 — 8 exons

Exon	Start	End
ENSE00000699817	55277642	55277846
ENSE00001175478	55265278	55265389
ENSE00001175486	55265886	55265982
ENSE00001175493	55266131	55266286
ENSE00001175500	55274398	55274622
ENSE00001179279	55279399	55279702
ENSE00002835814	55280035	55280110
ENSE00002951641	55262223	55262682

Expression profiles

Bgee: expression breadth ubiquitous, 270 present calls, max score 96.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 32.4712 / max 134.6519, expressed in 1811 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
182770	31.0111	1808
182769	0.6902	226
182772	0.4765	232
182771	0.2934	143

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
nucleus accumbens	UBERON:0001882	96.74	gold quality
right uterine tube	UBERON:0001302	96.38	gold quality
caudate nucleus	UBERON:0001873	96.15	gold quality
putamen	UBERON:0001874	96.01	gold quality
right frontal lobe	UBERON:0002810	95.09	gold quality
apex of heart	UBERON:0002098	94.12	gold quality
cingulate cortex	UBERON:0003027	93.97	gold quality
anterior cingulate cortex	UBERON:0009835	93.79	gold quality
amygdala	UBERON:0001876	93.74	gold quality
mucosa of transverse colon	UBERON:0004991	93.59	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.31	gold quality
prefrontal cortex	UBERON:0000451	93.29	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.04	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	92.27	gold quality
neocortex	UBERON:0001950	91.96	gold quality
lower esophagus mucosa	UBERON:0035834	91.96	gold quality
telencephalon	UBERON:0001893	91.92	gold quality
frontal cortex	UBERON:0001870	91.78	gold quality
frontal lobe	UBERON:0016525	91.75	gold quality
hypothalamus	UBERON:0001898	91.55	gold quality
forebrain	UBERON:0001890	91.46	gold quality
lower esophagus	UBERON:0013473	91.37	gold quality
lower esophagus muscularis layer	UBERON:0035833	91.37	gold quality
right atrium auricular region	UBERON:0006631	91.30	gold quality
hindlimb stylopod muscle	UBERON:0004252	91.24	gold quality
epithelium of bronchus	UBERON:0002031	91.19	gold quality
gastrocnemius	UBERON:0001388	91.10	gold quality
cerebral cortex	UBERON:0000956	91.06	gold quality
heart left ventricle	UBERON:0002084	91.01	gold quality
bronchus	UBERON:0002185	90.97	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.15
E-HCAD-5	no	2.24

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

23 targeting HSPBP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-3156-3P	99.76	66.72	939
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-3682-3P	99.58	67.63	865
HSA-MIR-3911	99.38	66.95	1087
HSA-MIR-1276	99.36	68.18	1642
HSA-MIR-5703	99.10	67.09	2053
HSA-MIR-3138	98.41	67.53	744
HSA-MIR-615-5P	98.10	63.76	591
HSA-MIR-4800-5P	97.22	65.91	324
HSA-MIR-10398-5P	97.12	64.94	1051
HSA-MIR-4693-3P	95.23	65.92	735
HSA-MIR-542-5P	87.47	60.42	76

Literature-anchored findings (GeneRIF, showing 25)

• Results report cooperative interactions involving Hsp70, Hsp40, and TPR1 that enhance Hsp70-dependent folding of chemically denatured substrates. (PMID:14503850)
• Detection of hsp70 may be used as the screening marker for diagnosis of polycyclic aromatic hydrocarbons (PAHs)-related lung cancer related lung cancer, and may supplement the diagnostic value of conventional cytology. (PMID:14761400)
• HspBP1 interferes with the CHIP-induced degradation of immature forms of the cystic fibrosis transmembrane conductance regulator (CFTR) and stimulates CFTR maturation. (PMID:15215316)
• BAG2 binds to the carboxyl terminus of Hsp70-interacting protein (CHIP) and provides a cochaperone-dependent regulatory mechanism for preventing unregulated ubiquitylation of misfolded proteins by CHIP (PMID:16169850)
• The results demonstrate that Hsp70 and HspBP1 are not coordinately regulated but provide evidence that an increase in the ratio of HspBP1 to Hsp70 correlates with apoptosis, in a similar way to reducing the amount of Hsp70. (PMID:16677834)
• Stress-induced heat shock protein 70 (Hsp70) effectively protects cells against ultraviol ray-induced apoptosis in melanocytes bu penetrating mitchondrial and lysosomal membranes. (PMID:16950797)
• Here, we report that upon the formation of huntingtin aggregates; endogenous cytosolic huntingtin, Hsc70/Hsp70 (heat shock protein and cognate protein of 70kDa) and syntaxin 1A become aggregate-centered. (PMID:17208201)
• that HspBP1, by antagonizing the prosurvival activity of Hsp70, sensitizes tumor cells to cathepsin-mediated cell death. (PMID:17855353)
• Association between endogenous LAP2alpha and Hsp70 in non-transfected cells was confirmed by co-immunoprecipitation. (PMID:18261988)
• The two chaperones, HSP72 and HSPBP1, interact both physically and functionally, leading to the activation of th EGFR-ERK1/2 signalling pathway. (PMID:18986301)
• Results indicate that low HspBP1 expression could be a marker of tumor aggressiveness. (PMID:18987994)
• Our data suggest that HIP may prevent inclusion formation by facilitating the constitutive HSC70 refolding cycle and possibly by preventing aggregation. (PMID:19183265)
• HspBP1 may play a role in tumor (dys)regulation of chaperone proteins (PMID:19659607)
• High gene expression of HspBP1 is associated with leukemia. (PMID:20694586)
• shown that HspBP1 binds Tag7 in the conditioned medium of tumor CSML0 cells, thereby preventing formation of the cytotoxic Tag7-Hsp70 complex (PMID:22037021)
• BAG-1M and HspBP1 had differential impacts on the dynamic composition of steroid receptor folding complexes (PMID:24454860)
• Oxidative stress, inducing formation of disulfide bond, can affect stability and conformational mobility of human HspB1. (PMID:24898092)
• our results clearly show that HspBP1 acts as an endogenous negative regulator of HIV-1 gene-expression and replication by suppressing NF-kappaB-mediated activation of viral transcription. (PMID:26538602)
• downregulation of Hsp70 and HspBP1 represents a unique feature of patients with preterm prelabor rupture of membranes (PMID:28497897)
• Findings indicate a critical role of HspBP1 in differential CHIP/Hsp70 activities in neuronal and glial cells and the greater neuronal vulnerability to misfolded proteins in neurodegenerative diseases. (PMID:28847953)
• Circulating HspBp1 is associated with progression of HIV infection and can be used as a new marker to predict the prognosis and management of HIV infection (PMID:30786116)
• The Co-Chaperone HspBP1 Is a Novel Component of Stress Granules that Regulates Their Formation. (PMID:32235396)
• HSPBP1 facilitates cellular RLR-mediated antiviral response by inhibiting the K48-linked ubiquitination of RIG-I. (PMID:33713958)
• HspBP1 is a dual function regulatory protein that controls both DNA repair and apoptosis in breast cancer cells. (PMID:35387978)
• The cochaperone HspBP1 binds to and inhibits Hsp70 activity. (PMID:9830037)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	hspbp1	ENSDARG00000102937
mus_musculus	Hspbp1	ENSMUSG00000063802
rattus_norvegicus	Hspbp1	ENSRNOG00000017795
drosophila_melanogaster	CG10973	FBGN0036306

Paralogs (1): SIL1 (ENSG00000120725)

Protein

Protein identifiers

Hsp70-binding protein 1 — Q9NZL4 (reviewed: Q9NZL4)

Alternative names: Heat shock protein-binding protein 1, Hsp70-binding protein 2, Hsp70-interacting protein 1, Hsp70-interacting protein 2

All UniProt accessions (7): Q9NZL4, K7EKM6, K7EL16, K7EMM7, K7EN20, K7EQQ0, K7ERT9

UniProt curated annotations — full annotation on UniProt →

Function. Inhibits HSPA1A chaperone activity by changing the conformation of the ATP-binding domain of HSPA1A and interfering with ATP binding. Interferes with ubiquitination mediated by STUB1 and inhibits chaperone-assisted degradation of immature CFTR.

Subunit / interactions. Interacts with the ATP-binding domain of HSPA1A. Detected in a ternary complex containing STUB1, HSPA1A and HSPBP1. Interacts with PGLYRP1; this interaction blocks the cytotoxic activity of the PGLYRP1-HSPA1A complex.

Tissue specificity. Ubiquitous.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NZL4-1	1	yes
Q9NZL4-2	2
Q9NZL4-3	3

RefSeq proteins (3): NP_001123578, NP_001284529, NP_036399* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011989	ARM-like	Homologous_superfamily
IPR013918	Nucleotide_exch_fac_Fes1	Domain
IPR016024	ARM-type_fold	Homologous_superfamily
IPR050693	SIL1/FES1/HPBP1	Family

Pfam: PF08609

UniProt features (36 total): helix 20, repeat 4, splice variant 3, sequence variant 2, modified residue 2, chain 1, sequence conflict 1, turn 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
1XQR	X-RAY DIFFRACTION	2.1
8X87	X-RAY DIFFRACTION	2.2
1XQS	X-RAY DIFFRACTION	2.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NZL4-F1	84.36	0.68

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 351, 356

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 151 (showing top): GOBP_REGULATION_OF_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_PROCESS, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_POSITIVE_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_PROTEIN_MATURATION, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS, HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_DN, GOBP_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_PROTEIN_FOLDING, MORI_PRE_BI_LYMPHOCYTE_UP, CYTAGCAAY_UNKNOWN

GO Biological Process (3): protein folding (GO:0006457), positive regulation of protein ubiquitination (GO:0031398), positive regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032436)

GO Molecular Function (5): adenyl-nucleotide exchange factor activity (GO:0000774), enzyme inhibitor activity (GO:0004857), ubiquitin protein ligase binding (GO:0031625), molecular sequestering activity (GO:0140313), protein binding (GO:0005515)

GO Cellular Component (2): obsolete extracellular space (GO:0005615), endoplasmic reticulum (GO:0005783)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular process	1
protein maturation	1
protein ubiquitination	1
regulation of protein ubiquitination	1
positive regulation of protein modification by small protein conjugation or removal	1
regulation of proteasomal ubiquitin-dependent protein catabolic process	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
positive regulation of proteasomal protein catabolic process	1
positive regulation of ubiquitin-dependent protein catabolic process	1
ATP binding	1
ADP binding	1
ATPase regulator activity	1
catalytic activity	1
enzyme regulator activity	1
molecular function inhibitor activity	1
ubiquitin-like protein ligase binding	1
molecular_function	1
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

4104 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HSPBP1	HSPA4	P34932	997
HSPBP1	HSPA8	P11142	984
HSPBP1	DNAJB1	P25685	942
HSPBP1	STUB1	Q9UNE7	897
HSPBP1	HSP90AB1	P08238	890
HSPBP1	HSP90AA1	P07900	854
HSPBP1	UBE2D1	P51668	837
HSPBP1	STIP1	P31948	782
HSPBP1	BRSK1	Q8TDC3	760
HSPBP1	GRPEL1	Q9HAV7	755
HSPBP1	TRIM21	P19474	745
HSPBP1	BAG1	Q99933	740
HSPBP1	DNAJA1	P31689	683
HSPBP1	HYOU1	Q9Y4L1	667
HSPBP1	HSPA1A	P08107	629

IntAct

124 interactions, top by confidence:

A	B	Type	Score
CSNK2B	CSNK2A2	psi-mi:“MI:0914”(association)	0.960
HSPA8	HSPBP1	psi-mi:“MI:0915”(physical association)	0.930
HSPBP1	HSPA8	psi-mi:“MI:0915”(physical association)	0.930
HSPBP1	HSPA2	psi-mi:“MI:0915”(physical association)	0.920
HSPA2	HSPBP1	psi-mi:“MI:0915”(physical association)	0.920
MED4	MED19	psi-mi:“MI:0914”(association)	0.900
HSPA8	BAG2	psi-mi:“MI:2364”(proximity)	0.860
GMNN	MCIDAS	psi-mi:“MI:0914”(association)	0.770
HSPA8	GAK	psi-mi:“MI:0914”(association)	0.760
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
VCP	UBXN8	psi-mi:“MI:0914”(association)	0.690
HSPBP1	NOTCH2NLA	psi-mi:“MI:0915”(physical association)	0.670
NOTCH2NLA	HSPBP1	psi-mi:“MI:0915”(physical association)	0.670
HSF1	KPNA3	psi-mi:“MI:0914”(association)	0.640
HMCES	HSPA8	psi-mi:“MI:0914”(association)	0.640

BioGRID (256): HSPBP1 (Two-hybrid), HSPBP1 (Two-hybrid), NOTCH2NL (Two-hybrid), HSPA8 (Affinity Capture-MS), HSPA6 (Affinity Capture-MS), EDRF1 (Affinity Capture-MS), NT5C2 (Affinity Capture-MS), ELF2 (Affinity Capture-MS), HSPBP1 (Two-hybrid), HSPBP1 (Two-hybrid), ACTR2 (Co-fractionation), HSPBP1 (Co-fractionation), HSPBP1 (Co-fractionation), HSPBP1 (Co-fractionation), HSPBP1 (Co-fractionation)

ESM2 similar proteins: A5A779, A6NLP5, A8E7I5, C5IJB0, F1MX48, I3L5V6, M0RDU0, O35465, O95801, P23610, P36915, P36916, P97452, Q00558, Q08602, Q0P5H9, Q14137, Q14318, Q17QX2, Q2TBQ9, Q2YD98, Q3B7U9, Q3SZV0, Q4R588, Q4R8D2, Q5EA80, Q5NVK5, Q5R8E2, Q5RA07, Q5TM59, Q66H45, Q68G30, Q6AY79, Q6IMX7, Q6P597, Q6P9Z4, Q6SZW1, Q7YR35, Q810A3, Q8C3I8

Diamond homologs: A1DLW4, A2R4I6, A3LUY1, O43030, P0CN68, P0CN69, P38260, Q0CH70, Q0V4C4, Q1E3S4, Q2GXZ7, Q2U9E2, Q4I624, Q4P7F2, Q4R588, Q4WDH3, Q59NN8, Q5AYT7, Q6BLA1, Q6C239, Q6CNM7, Q6FM01, Q6IMX7, Q6NUA7, Q75B89, Q99P31, Q9C239, Q9NZL4, Q08199, Q32KV6, Q6BTV5, Q6CKV0, Q6P6S4, Q9EPK6, Q9H173, Q9VBV5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 113 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Attenuation phase	5	25.5×	2e-04
Cellular response to heat stress	5	24.6×	2e-04
Dengue Virus Genome Translation and Replication	5	19.8×	4e-04
Aggrephagy	6	18.6×	1e-04
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	7	16.9×	4e-05
Regulation of HSF1-mediated heat shock response	9	15.7×	3e-06
Autophagy	6	11.1×	1e-03
The role of GTSE1 in G2/M progression after G2 checkpoint	5	10.1×	5e-03

GO biological processes:

GO term	Partners	Fold	FDR
protein refolding	6	37.1×	9e-06
cellular response to heat	6	20.4×	2e-04
response to unfolded protein	5	14.9×	3e-03
protein folding	9	9.2×	2e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

78 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	59
Likely benign	5
Benign	2

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
564606	GRCh37/hg19 19q13.42-13.43(chr19:54196216-58759679)x3	Pathogenic
59116	GRCh38/hg38 19q13.33-13.43(chr19:47908540-58539965)x3	Pathogenic

SpliceAI

1400 predictions. Top by Δscore:

Variant	Effect	Δscore
19:55265286:C:CA	donor_gain	1.0000
19:55265385:CCAGG:C	acceptor_gain	1.0000
19:55265386:CAGGC:C	acceptor_gain	1.0000
19:55265388:GG:G	acceptor_gain	1.0000
19:55265390:C:CC	acceptor_gain	1.0000
19:55266284:GACC:G	acceptor_loss	1.0000
19:55266285:ACC:A	acceptor_loss	1.0000
19:55266286:CCT:C	acceptor_loss	1.0000
19:55266287:C:CA	acceptor_loss	1.0000
19:55274393:CTCA:C	donor_loss	1.0000
19:55274394:TCA:T	donor_loss	1.0000
19:55274395:CA:C	donor_loss	1.0000
19:55274396:A:AC	donor_gain	1.0000
19:55274396:A:AT	donor_loss	1.0000
19:55274397:C:CC	donor_gain	1.0000
19:55274397:C:CG	donor_loss	1.0000
19:55274397:CAG:C	donor_gain	1.0000
19:55274397:CAGG:C	donor_gain	1.0000
19:55274629:C:CT	acceptor_gain	1.0000
19:55274631:C:CT	acceptor_gain	1.0000
19:55277637:GGTAC:G	donor_loss	1.0000
19:55277638:GTACC:G	donor_loss	1.0000
19:55277639:TACCT:T	donor_loss	1.0000
19:55277640:AC:A	donor_loss	1.0000
19:55277641:CCTGC:C	donor_loss	1.0000
19:55277842:CGCCT:C	acceptor_gain	1.0000
19:55277845:CT:C	acceptor_gain	1.0000
19:55277847:C:CC	acceptor_gain	1.0000
19:55277848:T:C	acceptor_loss	1.0000
19:55277855:C:CT	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000144911 (19:55280969 G>A,T), RS1000229684 (19:55269832 C>T), RS1000419104 (19:55270285 T>A), RS1000434554 (19:55263713 C>G,T), RS1000619537 (19:55268804 G>A), RS1000709305 (19:55275018 A>C), RS1000751749 (19:55269072 A>G,T), RS1000819574 (19:55270741 TCCACACATC>T), RS1000823688 (19:55274304 T>C), RS1000876135 (19:55274465 C>G,T), RS1001022531 (19:55278967 C>G), RS1001061472 (19:55279493 G>A), RS1001496914 (19:55276719 G>C), RS1001547872 (19:55276917 C>A,T), RS1001554938 (19:55279892 T>C)

Disease associations

OMIM: gene MIM:612939 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010653_3	Thyroid stimulating hormone levels	1.000000e-08

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724653 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.56	Kd	273	nM	MOLIBRESIB
6.16	IC50	690	nM	MOLIBRESIB

PubChem BioAssay actives

2 with measured affinity, of 7 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179230: Binding affinity against HSPBP1 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.2730	uM

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, increases expression	2
Smoke	decreases expression, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
bisphenol F	affects cotreatment, increases expression	1
alpha-pinene	increases oxidation, increases abundance, affects cotreatment	1
bisphenol A	affects expression	1
beta-lapachone	decreases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
K 7174	decreases expression	1
(+)-JQ1 compound	decreases expression	1
Acetaminophen	decreases expression	1
Acrolein	increases oxidation, increases abundance, affects cotreatment	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Caffeine	increases phosphorylation	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Indomethacin	affects cotreatment, increases expression	1
Isoniazid	decreases expression	1
Ivermectin	decreases expression	1
Ozone	increases oxidation, increases abundance, affects cotreatment	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	increases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697673	Binding	Inhibition of HSPBP1 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.